Irreversible electroporation for pelvic tumors that have come back
Follows adults treated with irreversible electroporation for recurrent pelvic tumors, checking safety and tumor control.
Plain-language title generated from the registry record
Registry title: Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Key facts
- Where
- Amsterdam, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose pelvic tumor has come back and who are having irreversible electroporation (IRE). Other local treatments such as surgery or radiotherapy are not an option for them.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- A pelvic tumor that has come back (recurrence), with disease that can be measured on scans (CT, MRI or PET-CT) done no more than 6 weeks before treatment.
- Earlier treatment
- The tumor board must have found other local treatments, such as surgery or stereotactic body radiation therapy, unsuitable. IRE is the treatment given.
Main reasons for not taking part
- The treated tumor was biopsied just before treatment and proved to be a benign (non-cancerous) lesion
- Not enough data registered
- Not enough follow-up
Read by machine on 9 November 2026.
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Amsterdam UMC, location VUmc
- Trial code
- NCT07782164
- Record updated
- 28 August 2026
- Original description
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE) in men and women over the age of 18 who receive IRE for recurrence of pelvic tumors not suitable for other local treatment options such as surgery, thermal ablation, and radiotherapy. The main question it aims to answer is whether IRE is safe in this population, and secondarily, whether it is effective in controlling local tumor recurrence.Read full original descriptionShow less
Irreversible Electroporation (IRE) of Recurrent Pelvic Tumors: the PELFIRE Study.
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE) in men and women over the age of 18 who receive IRE for recurrence of pelvic tumors not suitable for other local treatment options such as surgery, thermal ablation, and radiotherapy. The main question it aims to answer is whether IRE is safe in this population, and secondarily, whether it is effective in controlling local tumor recurrence.
Inclusion: Measurable disease described on pre-treatment imaging (CT/MRI/PET-CT) (max 6 weeks prior); IRE of a recurrent pelvic tumor; Unsuitable for other local therapies (surgery/stereotactic body radiation therapy) as described during the multidisciplinary tumor board.
Exclusion: If the treated tumor was biopsied directly prior to MWA and pathology proves the lesion to represent a benign entity; Inadequate or insufficient data registered; Inadequate or insufficient follow-up.